Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of R-130964, the Active Metabolite of Clopidogrel, in Healthy Subjects.

Trial Profile

Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of R-130964, the Active Metabolite of Clopidogrel, in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2011

At a glance

  • Drugs Clopidogrel; Edivoxetine
  • Indications Attention-deficit hyperactivity disorder; Depressive disorders; Thrombosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 27 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top